![Stylized image of a human eye.](https://aurionbiotech.com/wp-content/uploads/2024/01/homepage-banner.webp)
Millions of People Suffer from Sight-Threatening Corneal Endothelial Diseases
Our Cell Therapy Has the Potential to
Restore Their Vision
![Prix Galien USA award logo](https://aurionbiotech.com/wp-content/uploads/2024/01/prix-galien-usa.webp)
Company recognized for innovations in clinically validated cell therapy for corneal endothelial dystrophies
![Frontal group shot of the Aurion team](https://aurionbiotech.com/wp-content/uploads/2024/01/aurion-team.webp)
Get to know us.
We are a clinical-stage biotech company. We aim to restore vision to all who need it by developing a platform of innovative, accessible, and effective advanced therapies. Our first candidate is a patented cell therapy treatment for corneal endothelial disease.
Latest News
-
Why BTD / RMAT Designations Matter
Read More -
Aurion Biotech Receives Breakthrough Therapy Designation and Regenerative Medicine Advanced Therapy Designation for Its Drug Candidate AURN001
Read More -
Aurion Biotech CEO Greg Kunst Named Ernst & Young 2024 Entrepreneur of the Year Mountain West Region
Read More